| 0.9 -0.017 (-1.83%) | 10-29 11:36 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.18 | 1-year : | 1.3 |
| Resists | First : | 1.01 | Second : | 1.12 |
| Pivot price | 0.9  |
|||
| Supports | First : | 0.85 | Second : | 0.7 |
| MAs | MA(5) : | 0.88  |
MA(20) : | 0.92 |
| MA(100) : | 1.02 |
MA(250) : | 1.12 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.3 |
D(3) : | 21.4 |
| RSI | RSI(14): 42.1 |
|||
| 52-week | High : | 4.19 | Low : | 0.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PHIO ] has closed above bottom band by 47.3%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.92 - 0.92 | 0.92 - 0.93 |
| Low: | 0.86 - 0.86 | 0.86 - 0.87 |
| Close: | 0.91 - 0.92 | 0.92 - 0.92 |
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Fri, 23 Oct 2026
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Fri, 23 Oct 2026
Phio Pharmaceuticals Corp. Estimates – NASDAQ:PHIO - TradingView
Mon, 19 Oct 2026
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - Yahoo Finance
Wed, 14 Oct 2026
Phio Pharmaceuticals Completes Commercial cGMP Batch of PH-762 - The Clinical Trial Vanguard
Tue, 13 Oct 2026
Phio Pharmaceuticals completes first commercial-scale cGMP batch of PH-762, supporting Phase 2b start in Q1 2027 - TradingView
Tue, 13 Oct 2026
A cancer drug's first production-scale batch is complete; a clinical study is planned for early 2027. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 8 (%) |
| Held by Institutions | 10.2 (%) |
| Shares Short | 89 (K) |
| Shares Short P.Month | 222 (K) |
| EPS | -1.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -65.8 % |
| Return on Equity (ttm) | -113.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.74 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.7 |
| PEG Ratio | 0 |
| Price to Book value | 0.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|